From epidemiology and neurodevelopment to antineoplasticity. Medroxyprogesterone reduces human glial tumor growth in vitro and C6 glioma in rat brain in vivo


Altinoz M. A., Nalbantoglu J., ÖZPINAR A., Ozcan M. E., Del Maestro R. F., Elmaci I.

CLINICAL NEUROLOGY AND NEUROSURGERY, vol.173, pp.20-30, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 173
  • Publication Date: 2018
  • Doi Number: 10.1016/j.clineuro.2018.07.012
  • Journal Name: CLINICAL NEUROLOGY AND NEUROSURGERY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED)
  • Page Numbers: pp.20-30
  • Keywords: Medroxyprogesterone, Progesterone analogues, Dexamethasone, Temozolomide, Glioblastoma, BREAST-CANCER CELLS, PROGESTERONE-RECEPTOR, PHOSPHATIDYLINOSITOL 3-KINASE, REPRODUCTIVE FACTORS, ENDOMETRIAL CANCER, ADENOVIRUS RECEPTOR, ACETATE MPA, RISK, INVASION, DIFFERENTIATION
  • Acibadem Mehmet Ali Aydinlar University Affiliated: Yes

Abstract

Objective: Glial tumor growth may accelerate during gestation, but epidemiological studies consistently demonstrated that parousity reduces life long risk of glial tumors. Pregnancy may also accelerate growth of medulloblastoma and meningioma, but parousity does not confer protection against these tumors. We were the first to show that medroxyprogesterone acetate (MPA) reduces rat C6 glioma growth in vitro. Now we aimed to determine the effects of MPA on human brain cancers (particularly glioblastoma) in vitro and C6 glioma in vivo.